Transcriptomics

Dataset Information

4

Distinct perturbation of the translatome by the anti-diabetic drug metformin


ABSTRACT: Reduced cancer incidence has been reported among type II diabetics treated with metformin. Metformin exhibits anti-proliferative and anti-neoplastic effects associated with inhibition of mTORC1, but the mechanisms are poorly understood. We provide the first genome-wide analysis of translational targets of canonical mTOR inhibitors (rapamycin and PP242) and metformin, revealing that metformin controls gene expression at the level of mRNA translation to an extent comparable to that of canonical mTOR inhibitors. Importantly, metformin's anti-proliferative activity can be explained by selective translational suppression of mRNAs encoding cell cycle regulators via the mTORC1/4E-BP pathway. Thus, metformin selectively inhibits mRNA translation of encoded proteins that promote neoplastic proliferation, motivating further studies of this compound and related biguanides in cancer prevention and treatment. MCF7 cells were treated with rapamycin, metformin or PP242 at concentrations that inhibited proliferation to 50% of control. Both cytoplasmic and polysome-associated mRNA was extracted from treatments and a vehicle treated control and probed with microarrays.

ORGANISM(S): Homo sapiens  

SUBMITTER: Nahum Sonenberg   Ola Larsson 

PROVIDER: E-GEOD-36847 | ArrayExpress | 2012-05-20

SECONDARY ACCESSION(S): GSE36847PRJNA156903

REPOSITORIES: GEO, ArrayExpress

Similar Datasets

2011-03-15 | E-GEOD-27784 | ArrayExpress
2011-03-15 | GSE27784 | GEO
2014-09-11 | E-GEOD-61289 | ArrayExpress
| GSE92598 | GEO
2011-08-02 | E-GEOD-27982 | ArrayExpress
2011-08-02 | E-GEOD-28021 | ArrayExpress
2019-09-30 | BIOMD0000000822 | BioModels
2013-01-29 | E-GEOD-35808 | ArrayExpress
2011-08-03 | GSE27982 | GEO
2011-08-03 | GSE28021 | GEO